Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rapp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in b
Rapport Therapeutics COO Cheryl Gault sold 10,000 shares of RAPP stock for about $416,000 in open-market trades on June 30, 2026, per an SEC Form 4. The sale reduced her direct holdings by 6.25% to 149,914 shares, worth about $5.9 million. The article notes RAPP shares were up 223.67% year over year as of July 1, 2026.
Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0002012593 0002012593 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
Over the past 7 days, alphai's AI scored 1 news story mentioning RAPP (Rapport Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RAPP coverage spans financial news, earnings and corporate actions.
In the last 30 days, RAPP insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($421K). The most active reporter was Ceesay Abraham, Chief Executive Officer, with 4 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
New clinical-program milestones (Phase 3 initiation, China IND approval, open-label safety trial) plus a long cash runway extend the near-term catalyst calendar for RAPP.
The Form 4 insider sale is unlikely to be a fundamental negative signal given the stated 10b5-1 structure, but it is a fresh, tradable datapoint for sentiment and positioning.
Routine corporate governance disclosure; unlikely to change near-term fundamentals but can affect sentiment around board/accounting continuity.
This is an insider sale by a significant holder, not a company fundamental update.
The recent insider stock sale by the company's CDO appears to be a planned transaction and does not necessarily indicate negative outlook. The positive Phase 2a trial results for RAP-219 and subsequent accelerated Phase 3 trials suggest strong development momentum. The stock's current overvaluation, as per InvestingPro, warrants caution for short-term traders, but long-term prospects remain supported by clinical progress.
alphai scores every news story that mentions RAPP with an AI model for sentiment and relevance, and aggregates insider trades from Rapport Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rapp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in b
6 min readRapport Therapeutics COO Cheryl Gault sold 10,000 shares of RAPP stock for about $416,000 in open-market trades on June 30, 2026, per an SEC Form 4. The sale reduced her direct holdings by 6.25% to 149,914 shares, worth about $5.9 million. The article notes RAPP shares were up 223.67% year over year as of July 1, 2026.
6 min readRapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0002012593 0002012593 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
2 min readThird Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. (RAPP) at $40.05 ($0.74M total) on 2026-05-26 under a Rule 10b5-1 trading plan.
2 min readRapport Therapeutics' Chief Development Officer, Yeleswaram Krishnaswamy, sold 20,225 shares of the company's common stock for over $808,000 on April 17, 2026, through a pre-arranged trading plan. Despite the sale, the company's stock has seen a significant annual increase, though it is currently considered overvalued according to InvestingPro. Meanwhile, Rapport Therapeutics recently announced positive Phase 2a trial results for its epilepsy drug RAP-219, leading to accelerated Phase 3 trials and reiterated "Buy" ratings from several analysts.
3 min readRapport Therapeutics (RAPP) will present new 8-week follow-up data from its Phase 2a trial of RAP-219 for focal onset seizures at the 2026 American Academy of Neurology Annual Meeting. The company's investment narrative hinges on RAP-219's ability to provide clinically meaningful seizure control with good tolerability, but faces risks due to no revenue, ongoing losses, and recent dilution. While the stock has seen a significant gain, Simply Wall St's valuation report suggests it may be overpriced, with a community fair value estimate of US$53.60.
4 min readMorgan Stanley Smith Barney LLC has filed a Form 144 indicating a proposed sale of 360 shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) common stock. The filing also disclosed 10b5-1 sales of 10,115 shares on March 25, 2026, for gross proceeds of $303,354.24. As of April 8, 2026, Rapport Therapeutics has 47,792,943 shares outstanding.
2 min readRapport Therapeutics COO Cheryl Gault sold 10,000 shares of common stock for a total of $281,857 on March 30, 2026, under a pre-arranged trading plan. This sale occurred after a significant 176% surge in the company's stock over the past year. The company recently announced positive fiscal year 2025 earnings and advanced timelines for Phase 3 studies of RAP-219, leading several analysts to reiterate their Buy ratings with increased price targets.
2 min readRapport Therapeutics' COO, Cheryl Gault, sold 10,000 shares of common stock in open-market transactions on March 30, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. The sales were conducted in two tranches at weighted average prices of $28.0401 and $28.5530, totaling approximately $281,857. Following these transactions, Gault directly holds 159,914 shares.
2 min readThe average of price targets set by Wall Street analysts indicates a potential upside of 104.5% in Rapport Therapeutics, Inc. (RAPP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in ...
4 min read
